Every 10-Q that Relay Therapeutics, Inc. (RLAY) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow RLAY and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full RLAY filings page.
Relay Therapeutics (RLAY) filed its Q3 2025 report, highlighting continued R&D progress and a stronger balance sheet cushion. The company reported a net loss of $74.1M for the quarter versus $88.1M a year ago, as operating expenses declined with research and development at $68.3M and general and administrative at $12.1M. Quarterly revenue was $0; year-to-date revenue was $8.4M, primarily from the Elevar agreement tied to lirafugratinib.
Cash and investments totaled $596.4M ($91.6M cash and equivalents; $504.9M investments) at September 30, 2025, and management states this can fund operations into 2029. Shares outstanding were 173,322,385 as of October 31, 2025. The Genentech collaboration for migoprotafib ended effective January 7, 2025. Relay advanced RLY‑2608, initiating the global Phase 3 ReDiscover‑2 trial in HR+/HER2‑ breast cancer and reported interim PFS signals in combination with fulvestrant. Lease actions reduced footprint, including a terminated 399 Binney lease and a new, smaller One Kendall Square office lease.